NCT07107204View on ClinicalTrials.gov

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

April 30, 2028

Conditions
Relapsed or Refractory Hematologic MalignanciesLeukemiaLymphomaMultiple Myeloma (MM)
Interventions
DRUG

BT02

BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Sponsors
All Listed Sponsors
lead

Biotroy Therapeutics

INDUSTRY

NCT07107204 - A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | Biotech Hunter | Biotech Hunter